发明名称 |
PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES |
摘要 |
The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. Such compositions may further comprise a monoglyceride, a free fatty acid or a combination of the foregoing, including, e.g., a eutectic mixture. WO 2015/187883 PCT/US2015/034078 . 1.00 - .. Nilotinib, 0.1 pM 0.40 ::'DMPC + Nilotinib, 0.1 pM Baseline 0.60 * e ' ..-Nilotinib, 0.1 pM DMPG + Nilotinib, 0.1 pM 0.40 0.00- ------- ,------------ Baseline |
申请公布号 |
AU2016266020(A1) |
申请公布日期 |
2017.02.02 |
申请号 |
AU20160266020 |
申请日期 |
2016.12.05 |
申请人 |
SignPath Pharma, Inc. |
发明人 |
Helson, Lawrence;Shopp, George M.;Bouchard, Annie;Majeed, Muhammed |
分类号 |
A61K31/685;A61K31/135;A61K31/661;A61P9/00 |
主分类号 |
A61K31/685 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|